About the Company
developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ZNTL News
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
Earnings Estimate Revisions for Zentalis Pharmaceuticals, Inc. This company is expected to earn -$4.49 per share for the fiscal year ending December 2023, which represents a year-over-year change ...
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
Zentalis Pharmaceuticals, Inc. (ZNTL) closed the last trading session at $14.71, gaining 21.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...
Zentalis Pharmaceuticals Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ...
Warning! GuruFocus has detected 2 Warning Sign with ZNTL. Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) released its 8-K filing on February 27, 2024, detailing the company's financial results for the ...
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
NEW YORK and SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically ...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically ...
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
Corporate Updates Anticipated Upcoming Milestones Full Year 2023 Financial Results About Azenosertib Zentalis ® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company discovering and ...
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically ...
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
NEW YORK and SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically ...
Loading the latest forecasts...